Download PDF
Dtsch Med Wochenschr 2009; 134(18): 949-954
DOI: 10.1055/s-0029-1220255
Konsensus | Review article
Diabetologie, Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York

Herausforderung Diabetestherapie: Effekte der Glitazone jenseits der Blutzuckerkontrolle

Challenge in diabetes therapy: Effects of thiazolidinediones beyond blood glucose controlG. Schernthaner1 , T. Forst2 , D. Gulba3 , W. Haberbosch4 , M. Hanefeld5 , G. Linß6 , W. März7 , H. Mehnert8 , C. Rosak9 , O. Schnell8 , J. Seufert10 , D. Tschöpe11 , E. Erdmann12
  • 11. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien
  • 2Institut für klinische Forschung und Entwicklung GmbH, Mainz
  • 3Kardiologie, Angiologie und Pulmologie, Innere Medizin I, Krankenhaus Düren GmbH
  • 4Klinik für Innere Medizin I, SRH Zentralklinikum Suhl GmbH
  • 5Forschungsbereich Endokrinologie und Stoffwechsel, Zentrum für Klinische Studien, GWT-TUD mbH, Dresden
  • 6Praxis für Kardiologie und Hypertensiologie, Oranienburg
  • 7Synlab Heidelberg, Medizinisches Versorgungszentrum für Labordiagnostik, Eppelheim
  • 8Institut für Diabetesforschung, München
  • 9Diabetologie, Krankenhaus Sachsenhausen des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Frankfurt am Main
  • 10Schwerpunkt Endokrinologie und Diabetologie, Abteilung Innere Medizin II, Universitätsklinikum Freiburg
  • 11Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen
  • 12Klinik III für Innere Medizin, Klinikum der Universität zu Köln
Further Information

Publication History

eingereicht: 9.10.2008

akzeptiert: 2.4.2009

Publication Date:
21 April 2009 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Nicht erst mit den Ergebnissen von ACCORD, ADVANCE und VADT wird deutlich, dass eine antihyperglykämische Therapie allein nicht ausreicht, um das kardiovaskuläre Risiko von Typ-2-Diabetikern zu reduzieren. Viele Untersuchungen weisen vielmehr darauf hin, dass manche Therapiestrategien sogar kontraproduktiv sein können. Für eine adäquate Therapie des Typ-2-Diabetes müssen zudem die Komorbiditäten wie diabetische Dyslipidämie, Hypertonie oder Nephropathie berücksichtigt werden.

Glitazone verringern die Insulinresistenz und ermöglichen so eine pathophysiologisch orientierte Therapie des Typ-2-Diabetes mellitus. Aufgrund ihres Wirkprinzips zeigen Glitazone über die Blutzuckerkontrolle hinaus günstige Effekte auf inflammatorische und atherogene Parameter, den Blutdruck sowie die Mikroalbuminurie. Pioglitazon verbessert zudem die Dyslipidämie und reduziert Tod, Herzinfarkt und Schlaganfall bei Hochrisikopatienten. Unsicherheit bezüglich des kardiovaskulären Risikos besteht noch bei Rosiglitazon. Zahlreiche randomisierte, kontrollierte Studien dokumentieren die Wirksamkeit und Sicherheit der Glitazone und bilden die Grundlage für eine evidenzbasierte Therapie, die über die Blutzuckerkontrolle hinausgeht.

Summary

Not just since the results of ACCORD, ADVANCE and VADT were published, it is clear that lowering blood glucose alone does not reduce the cardiovascular risk of patients with type 2 diabetes. In fact, many studies also indicate that some treatment strategies may even have adverse effects. To treat type 2 diabetes appropriately, the co-morbidities such as diabetic dyslipidaemia, hypertension or nephropathy must also be taken into account.

Thiazolidinediones reduce insulin resistance thus allowing to direct the treatment of type 2 diabetes towards its pathophysiologic origin. Due to their mechanism of action, thiazolidinediones not only lower blood glucose but have also beneficial effects on inflammatory and atherogenic parameters, blood pressure and microalbuminuria. Furthermore pioglitazone improves dyslipidaemia and reduces mortality, myocardial infarction and stroke in high risk patients. Effects of rosiglitazone on the cardiovascular risk are yet unclear. Numerous studies document the efficacy and safety of thiazolidinediones and provide a basis for an evidence-based therapeutic approach beyond blood glucose control.

Schlüsselwörter

Typ-2-Diabetes - Pioglitazon - Rosiglitazon - orale Antidiabetika - Insulin - Evidenz - kardiovaskuläres Risiko - Komorbiditäten

Keywords

type 2 diabetes - pioglitazone - rosiglitazone - oral antidiabetic drugs - insulin - evidence - cardiovascular risk - comorbidities

Literatur

  • 1 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
    Google Scholar
  • 2 Fachinformation actos. 2007
    Google Scholar
  • 3 Fachinformation AVANDIA. 2008
    Google Scholar
  • 4 Adler A I, Stratton I M, Neil H A. et al . Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.  BMJ. 2000;  321 412-419
    Google Scholar
  • 5 Bakris G, Viberti G, Weston W M. et al . Rosiglitazone reduces urinary albumin excretion in type II diabetes.  J Hum Hypertens. 2003;  17 7-12
    Google Scholar
  • 6 Betteridge D J, DeFronzo R A, Chilton R J. PROactive: time for a critical appraisal.  Eur Heart J. 2008;  29 969-983
    Google Scholar
  • 7 Caraballo P J, Heit J A, Atkinson E J. et al . Long-term use of oral anticoagulants and the risk of fracture.  Arch Intern Med. 1999;  159 1750-1756
    Google Scholar
  • 8 Chappuis B, Braun M, Stettler C. et al . Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.  Diabetes Metab Res Rev. 2007;  23 392-399
    Google Scholar
  • 9 Chiasson J L, Josse R G, Gomis R. et al . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.  JAMA. 2003;  290 486-494
    Google Scholar
  • 10 Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.  Arch Intern Med. 2004;  164 2097-2104
    Google Scholar
  • 11 Choi D, Kim S K, Choi S H. et al . Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.  Diabetes Care. 2004;  27 2654-2660
    Google Scholar
  • 12 Davidson M, Meyer P M, Haffner S. et al . Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.  Circulation. 2008;  117 2123-2130
    Google Scholar
  • 13 Deeg M A, Buse J B, Goldberg R B. et al . Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.  Diabetes Care. 2007;  30 2458-2464
    Google Scholar
  • 14 Derosa G, Cicero A F, Dangelo A. et al . Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.  Hypertens Res. 2005;  28 917-924
    Google Scholar
  • 15 Derosa G, D’Angelo A, Ragonesi P D. et al . Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.  J Clin Pharm Ther. 2006;  31 375-383
    Google Scholar
  • 16 Derosa G, Fogari E, Cicero A F. et al . Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.  Hypertens Res. 2007;  30 387-394
    Google Scholar
  • 17 Derosa G, Gaddi A V, Piccinni M N. et al . Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.  Pharmacotherapy. 2005;  25 637-645
    Google Scholar
  • 18 Dormandy J A, Charbonnel B, Eckland D J. et al . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
    Google Scholar
  • 19 Duckworth W, Abraira C, Moritz T. et al . Glucose control and vascular complications in veterans with type 2 diabetes.  N Engl J Med. 2009;  360 129-139
    Google Scholar
  • 20 Erdmann E. Herzinsuffizienz unter Glitazonen – was wissen wir heute?.  Dtsch Med Wochenschr. 2009;  134 154-158
    Google Scholar
  • 21 Erdmann E, Dormandy J A, Charbonnel B. et al . The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.  J Am Coll Cardiol. 2007;  49 1772-1780
    Google Scholar
  • 22 Erdmann E, Hanefeld M. Glitazone – eine antidiabetische Substanzklasse aus kardiologischer Sicht.  Dtsch Arztebl. 2004;  101 A 2954-A 2961
    Google Scholar
  • 23 Eurich D T, McAlister F A, Blackburn D F. et al . Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.  BMJ. 2007;  335 497
    Google Scholar
  • 24 Forst T, Karagiannis E, Lubben G. et al . Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.  Atherosclerosis. 2008;  197 311-317
    Google Scholar
  • 25 Forst T, Pfutzner A, Lubben G. et al . Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk – the PIOSTAT Study.  Metabolism. 2007;  56 491-496
    Google Scholar
  • 26 Geng D F, Jin D M, Wu W. et al . Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: A meta-analysis of randomized controlled trials.  Atherosclerosis. 2008;  202 521-528
    Google Scholar
  • 27 Gerstein H C, Miller M E, Byington R P. et al . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
    Google Scholar
  • 28 Goldberg R B, Kendall D M, Deeg M A. et al . A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.  Diabetes Care. 2005;  28 1547-1554
    Google Scholar
  • 29 Haffner S M, Greenberg A S, Weston W M. et al . Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.  Circulation. 2002;  106 679-684
    Google Scholar
  • 30 Hanefeld M, Brunetti P, Schernthaner G H. et al . One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.  Diabetes Care. 2004;  27 141-147
    Google Scholar
  • 31 Hanefeld M, Fischer S, Julius U. et al . Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.  Diabetologia. 1996;  39 1577-1583
    Google Scholar
  • 32 Hanefeld M, Marx N, Pfutzner A. et al . Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.  J Am Coll Cardiol. 2007;  49 290-297
    Google Scholar
  • 33 Holman R R, Paul S K, Bethel M A, Matthews D R, Neil H A. 10-year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1577-1589
    Google Scholar
  • 34 Home P D, Pocock S J, Beck-Nielsen H. et al . Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis.  N Engl J Med. 2007;  357 28-38
    Google Scholar
  • 35 Jeppesen J, Hein H O, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study.  Arterioscler Thromb Vasc Biol. 1997;  17 1114-1120
    Google Scholar
  • 36 Kahn S E, Haffner S M, Heise M A. et al . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
    Google Scholar
  • 37 Koro C E, Bowlin S J, Weiss S R. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.  Pharmacoepidemiol Drug Saf. 2005;  14 697-703
    Google Scholar
  • 38 Lago R M, Singh P P, Nesto R W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.  Lancet. 2007;  370 1129-1136
    Google Scholar
  • 39 Langenfeld M R, Forst T, Hohberg C. et al . Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.  Circulation. 2005;  111 2525-2531
    Google Scholar
  • 40 Lebovitz H E, Dole J F, Patwardhan R, Rappaport E B, Freed M I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2001;  86 280-288
    Google Scholar
  • 41 Lincoff A M, Wolski K, Nicholls S J, Nissen S E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.  JAMA. 2007;  298 1180-1188
    Google Scholar
  • 42 Margolis D J, Hoffstad O, Strom B L. Association between serious ischemic cardiac outcomes and medications used to treat diabetes.  Pharmacoepidemiol Drug Saf. 2008;  17 753-759
    Google Scholar
  • 43 Martens F M, Visseren F L, de Koning E J, Rabelink T J. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.  J Cardiovasc Pharmacol. 2005;  46 773-778
    Google Scholar
  • 44 Maru S, Koch G G, Stender M. et al . Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting.  Diabetes Care. 2005;  28 20-26
    Google Scholar
  • 45 Marx N, Froehlich J, Siam L. et al . Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.  Arterioscler Thromb Vasc Biol. 2003;  23 283-288
    Google Scholar
  • 46 Marx N, Wohrle J, Nusser T. et al . Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.  Circulation. 2005;  112 2792-2798
    Google Scholar
  • 47 Matthews D R, Charbonnel B H, Hanefeld M. et al . Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.  Diabetes Metab Res Rev. 2005;  21 167-174
    Google Scholar
  • 48 Mazzone T, Meyer P M, Feinstein S B. et al . Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.  JAMA. 2006;  296 2572-2581
    Google Scholar
  • 49 Mohanty P, Aljada A, Ghanim H. et al . Evidence for a potent antiinflammatory effect of rosiglitazone.  J Clin Endocrinol Metab. 2004;  89 2728-2735
    Google Scholar
  • 50 Nathan D M, Buse J B, Davidson M B. et al . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2009;  32 193-203
    Google Scholar
  • 51 Nesto R W, Bell D, Bonow R O. et al . Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.  Diabetes Care. 2004;  27 256-263
    Google Scholar
  • 52 Nichols G A, Koro C E, Gullion C M. et al . The incidence of congestive heart failure associated with antidiabetic therapies.  Diabetes Metab Res Rev. 2005;  21 51-57
    Google Scholar
  • 53 Nishio K, Sakurai M, Kusuyama T. et al . A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.  Diabetes Care. 2006;  29 101-106
    Google Scholar
  • 54 Nissen S E. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.  Am J Cardiol. 2005;  96 61F-68F
    Google Scholar
  • 55 Nissen S E, Nicholls S J, Sipahi I. et al . Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.  JAMA. 2006;  295 1556-1565
    Google Scholar
  • 56 Nissen S E, Nicholls S J, Wolski K. et al . Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.  JAMA. 2008;  299 1561-1573
    Google Scholar
  • 57 Nissen S E, Tuzcu E M, Schoenhagen P. et al . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.  JAMA. 2004;  291 1071-1080
    Google Scholar
  • 58 Nissen S E, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.  N Engl J Med. 2007;  356 2457-2471
    Google Scholar
  • 59 Patel A, MacMahon S, Chalmers J. et al . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
    Google Scholar
  • 60 Pfutzner A, Marx N, Lubben G. et al . Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.  J Am Coll Cardiol. 2005;  45 1925-1931
    Google Scholar
  • 61 Rao A D, Kuhadiya N, Reynolds K, Fonseca V A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies.  Diabetes Care. 2008;  31 1672-1678
    Google Scholar
  • 62 Raz I, Wilson P W, Strojek K. et al . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial.  Diabetes Care. 2009;  32 381-386
    Google Scholar
  • 63 Rejnmark L, Vestergaard P, Mosekilde L. Fracture risk in users of oral anticoagulants: a nationwide case-control study.  Int J Cardiol. 2007;  118 338-344
    Google Scholar
  • 64 Sarafidis P A, Bakris G L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.  Kidney Int. 2006;  70 1223-1233
    Google Scholar
  • 65 Scherbaum W, Ritz E. Prävention und Therapie der diabetischen Nephropathie.  Dtsch Arztebl. 2005;  102 A 137-143
    Google Scholar
  • 66 Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors.  Int J Clin Pract. 2009;  submitted in press
    Google Scholar
  • 67 Schernthaner G, Matthews D R, Charbonnel B. et al . Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.  J Clin Endocrinol Metab. 2004;  89 6068-6076
    Google Scholar
  • 68 Schneider C A, Ferrannini E, Defronzo R. et al . Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease.  J Am Soc Nephrol. 2008;  19 182-187
    Google Scholar
  • 69 Singh S, Loke Y K, Furberg C D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.  JAMA. 2007;  298 1189-1195
    Google Scholar
  • 70 Sourij H, Zweiker R, Wascher T C. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.  Diabetes Care. 2006;  29 1039-1045
    Google Scholar
  • 71 Souverein P C, Webb D J, Weil J G. et al . Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy.  Neurology. 2006;  66 1318-1324
    Google Scholar
  • 72 Sowers J R, Lester M A. Diabetes and cardiovascular disease.  Diabetes Care. 1999;  22 Suppl 3 C14-C20
    Google Scholar
  • 73 Stratton I M, Adler A I, Neil H A. et al . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
    Google Scholar
  • 74 Suzuki M, Takamisawa I, Yoshimasa Y, Harano Y. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone.  Diabetes Res Clin Pract. 2007;  76 12-17
    Google Scholar
  • 75 Takagi T, Yamamuro A, Tamita K. et al . Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.  Am Heart J. 2003;  146 E5
    Google Scholar
  • 76 Targownik L E, Lix L M, Metge C J. et al . Use of proton pump inhibitors and risk of osteoporosis-related fractures.  CMAJ. 2008;  179 319-326
    Google Scholar
  • 77 Turner R C, Millns H, Neil H A. et al . Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23).  BMJ. 1998;  316 823-828
    Google Scholar
  • 78 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs.  Epilepsia. 2004;  45 1330-1337
    Google Scholar
  • 79 Wilcox R, Bousser M G, Betteridge D J. et al . Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).  Stroke. 2007;  38 865-873
    Google Scholar
  • 80 Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).  Am Heart J. 2008;  155 712-717
    Google Scholar
  • 81 Yang Y X, Lewis J D, Epstein S, Metz D C. Long-term proton pump inhibitor therapy and risk of hip fracture.  JAMA. 2006;  296 2947-2953
    Google Scholar

Prof. Dr. Guntram Schernthaner

Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung

Juchgasse 25

A-1030 Wien

Phone: 0043/1711 65–2108

Fax: 0043/1711 65–2109

Email: guntram.schernthaner@meduniwien.ac.at

      >